Butterfly Network, Inc.

BFLY Healthcare Medical Devices

Butterfly Network, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $97.6 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 16.7% and free cash flow fell 113.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

7.25 0.60 −7.64%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−20.8×
Dividend yield
—
F-score
3/9
Altman Z
1.56
Beneish M
−3.30
Dividend safety
n/a

Insider Decisions trades per month

Total buys 13.07
Total sells 126.13
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 3 — — — — — — — 1 — —
Sell 4 6 3 1 5 2 1 2 12 3 4 1
Insider Ownership 17.52%

Capital & Financial Ratios $m

Market Cap 2,130.00
Revenue 112.14
Net Income (74.85)
Free Cash Flow (28.04)
Net Debt (124.66)
Current Ratio 4.06 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (20.80) (negative: loss-making)
P/S ratio 16.94 (above 10: high)
P/B ratio 10.03 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 10.71%
Next Y EPS Growth 32.00% (at or above 15%: strong)
Next Y revenue growth 24.78% (at or above 10%: strong)
Next 5Y EPS Growth 75.96% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/S against its own 10 years 79.66%
10-year low 10-year high
P/B against its own 10 years 87.45%
10-year low 10-year high
EV/Sales against its own 10 years 83.57%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 134 89 150 125
Receivables 13 21 27 35
Inventory 73 71 61 59
Other 3 6 2 2
231 193 249 238
2023 2024 2025 Q'26
Payables 5 4 5 4
ST’ Debt — — — —
Other 0 0 1 0
44 48 65 59

Compound Annual Growth %

10y 5y 3y
Sales — 16.11% 9.97%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (15.55%)

Revenue $m

Mar Jun Sep Dec Year
’26 27 33 — — —
’25 21 23 21 32 98
’24 18 21 21 22 82
’23 15 18 15 17 66
’22 16 19 20 19 73
’21 12 17 15 19 63
’20 9 12 10 16 46
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (14) (16) — — —
’25 (12) (7) (3) 9 (13)
’24 (21) (10) (8) (3) (42)
’23 (43) (26) (16) (13) (99)
’22 (54) (44) (42) (29) (169)
’21 (63) (37) (46) (43) (189)
’20 (20) (20) (22) (21) (82)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (17) — — —
’25 (12) (8) (4) 8 (16)
’24 (22) (11) (8) (4) (44)
’23 (45) (27) (17) (16) (105)
’22 (59) (51) (47) (31) (187)
’22 — — — — (169)
’21 (65) (37) (48) (47) (197)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.05) (0.05) — — —
’25 (0.06) (0.06) (0.13) (0.06) (0.31)
’24 (0.10) (0.07) (0.08) (0.08) (0.34)
’23 (0.17) (0.14) (0.13) (0.21) (0.65)
’22 (0.22) (0.18) (0.27) (0.17) (0.84)
’21 (0.01) (0.02) (0.07) (0.08) (0.19)
’20 (4.07) (3.85) (15.20) (3.74) (27.90)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 9.34 6.01 2.17 0.76 0.67 1.32

Analyst estimates 2026–2028

Powerpack
High — — — — 22.96 29.13 8.72 3.22 3.78 4.98
People
People Employees — — — — 260 463 330 225 190 220
Revenue/emp, $m — — — 0.00 0.18 0.14 0.22 0.29 0.43 0.44
Income, $m
Income, $m Revenue — — — 28 46 63 73 66 82 98
Gross margin, % — — — (75.75) (132.37) 27.26 53.77 25.58 59.51 46.85
EBT — — — (100) (163) (32) (169) (134) (73) (77)
EBT margin, % — — — (361.44) (351.78) (51.61) (229.84) (202.76) (88.38) (78.84)
Net income — 0 — (100) (163) (32) (169) (134) (72) (77)
Depreciation — — — 1 1 2 6 11 10 8
Per share, $
Per share, $ Revenue — — — 4.72 7.64 0.36 0.37 0.32 0.39 0.40
Earnings — — — (17.08) (27.90) (0.19) (0.84) (0.65) (0.34) (0.31)
Cash flow — — — (20.63) (13.49) (1.09) (0.85) (0.48) (0.20) (0.05)
Capex — — — (0.77) (0.39) (0.05) (0.09) (0.03) (0.01) (0.01)
Free cash flow — — — (21.39) (13.88) (1.13) (0.94) (0.51) (0.21) (0.06)
Book value — — — 0.00 (59.75) 2.58 1.63 1.07 0.80 0.79
Shares, m — — — 6 6 174 200 205 212 247
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 0.00 2.59 18.59 6.37 3.30 8.05 9.62
P/B — — — 11.95 0.00 2.60 1.44 0.99 3.91 4.79
EV/Sales — — — 0.00 2.46 12.69 3.87 2.08 7.62 8.63
EV/FCF — — — 0.00 (1.35) (4.03) (1.51) (1.31) (14.10) (52.50)
Cash, $m
Cash, $m Operating cash flow — — — (120) (82) (189) (169) (99) (42) (13)
Capex — — — (4) (2) (8) (18) (6) (3) (3)
Free cash flow — — — (125) (84) (197) (187) (105) (44) (16)
Balance, $m
Balance, $m Working capital — — — — 28 462 306 187 144 184
Total debt — — — — 54 28 30 — — —
Net debt — — — — (6) (423) (238) (134) (89) (150)
Shareholders’ equity — — — — (362) 448 325 220 169 196
Returns, %
Returns, % ROA — — — 0.00 (110.57) (9.01) (34.10) (37.04) (25.87) (27.89)
ROIC — — — 0.00 0.00 (484.73) (137.79) (106.30) (58.09) (118.73)
ROE — — — 0.00 44.97 (75.58) (43.65) (49.03) (37.28) (42.25)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Butterfly Network, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NEOG Neogen Corporation $2.7B — (loss-making) — (loss-making) +6.51% (above 0%: growing) n/m +135.75% (above 0%: growing) 47.35% (0.81%) Compare
TMDX TransMedics Group, Inc. $2.7B 16.0× 34.1× +20.70% (above 0%: growing) −59.22% (below 0%: shrinking) −87.62% (below 0%: shrinking) 59.59% 12.50% Compare
UFPT UFP Technologies, Inc. $2.3B 31.2× 23.6× +15.07% (above 0%: growing) +20.63% (above 0%: growing) −35.77% (below 0%: shrinking) 29.27% 16.15% Compare
BFLY Butterfly Network, Inc. $2.1B — (loss-making) — (loss-making) +39.47% (above 0%: growing) n/m −113.85% (below 0%: shrinking) 71.41% (41.90%)
AXGN AxoGen, Inc. $2.1B — (loss-making) — (loss-making) +23.06% (above 0%: growing) n/m −17.36% (below 0%: shrinking) 72.67% (3.09%) Compare
INSP Inspire Medical Systems, Inc. $2.0B 14.8× 93.5× −7.60% (below 0%: shrinking) n/m +322.84% (above 0%: growing) 85.48% (0.26%) Compare
ESTA Establishment Labs Holdings Inc. $1.8B — (loss-making) — (loss-making) +31.66% (above 0%: growing) n/m +2.75% (above 0%: growing) 70.64% (6.35%) Compare
ATEC Alphatec Holdings, Inc. $1.7B — (loss-making) — (loss-making) +15.07% (above 0%: growing) n/m −146.87% (below 0%: shrinking) 72.17% (0.89%) Compare
NVCR NovoCure Limited $1.7B — (loss-making) — (loss-making) +15.60% (above 0%: growing) n/m +105.68% (above 0%: growing) 77.61% (5.75%) Compare
Median of peers $2.1B 16.0× 34.1× +15.34% — −7.30% 71.41% (0.85%)

All 149 Medical Devices stocks →

Butterfly Network, Inc. (BFLY) key facts

  • Strength: Butterfly Network, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $97.6 million, up 19.0% from fiscal 2024.
  • Butterfly Network, Inc. (BFLY) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, BFLY traded at $7.25, a market capitalization of $2.1 billion.
  • Return on equity was −42.3% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 1.56 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Butterfly Network, Inc. (BFLY) Latest News

3 Aug

Impact 3 · transcript
stockrow.com/BFLY · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com